Immuno-Oncology in Bladder Cancer: The Urologist's Role - Noah Hahn
In this lecture, Noah Hahn presents the importance of immuno-oncology (IO) - checkpoint inhibitors. Patients with urothelial carcinoma are receiving approved immuno-oncologic drugs that significantly extend survival and are safer and more tolerable than chemotherapy. The efficacy of immuno-oncologic agents in advanced urothelial cancer has naturally raised questions about their potential use in earlier-stage disease. Could this approach achieve higher response rates and—most importantly—increase rates of cure for patients with muscle-invasive and non-muscle invasive
bladder cancer? The ongoing clinical trials are reviewed as are the results of the trials that have been recently completed.
Noah M. Hahn, MD, Associate Professor of Medicine, Department of Oncology and Urology, Johns Hopkins University School of Medicine